NWNN Clinical Lead Professor Michael Jenkinson leads landmark international brain tumour trial
A major international clinical trial led by Professor Michael Jenkinson has shown that post-operative radiotherapy can halve the risk of atypical meningioma recurrence, providing important new evidence to guide treatment decisions for patients worldwide.
Published in The Lancet on 25 September 2026, the ROAM/EORTC-1308 trial (Radiation versus Observation following surgical resection of Atypical Meningioma) found that administering radiotherapy after surgery reduced tumour recurrence rates from 30% to 14% over five years, without compromising patient quality of life.
Professor Jenkinson served as Chief Investigator and first author of the study, which was presented at the European Association of Neuro-Oncology (EANO) Annual Meeting 2026. Professor Jenkinson is Clinical Lead for the North West Neurosurgery Network (Cheshire and Merseyside), Consultant Neurosurgeon at The Walton Centre NHS Foundation Trust and RCS England / Sir John Fisher Foundation Chair of Surgical Trials at the University of Liverpool.
Commenting on the findings, Professor Jenkinson said: “The trial tackles a question that has been debated for many years: whether patients with atypical meningioma should receive radiotherapy after surgery. I’m proud that our team has been able to generate robust evidence that can help patients and clinicians make better-informed decisions.”
The significance of the research has already been recognised internationally, with the study receiving the EANO Best Oral Presentation for Clinical Research Award at the EANO 2026 conference. The findings are expected to influence future clinical practice and highlight the important contribution of NWNN clinical leaders to advancing neurosurgical research and improving outcomes for patients.
Read the full announcement on The Walton Centre website.
